Trial Profile
Immunogenicity and tolerability of a pandemic influenza A virus vaccine-H1N1, administered sequentially or simultaneously with a seasonal influenza virus vaccine [liposomal], for the prevention of pandemic and seasonal influenza virus infections in HIV-infected children and adolescents
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 18 Feb 2011
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary) ; Influenza virus vaccine liposomal (Primary) ; MF 59
- Indications Influenza A virus H1N1 subtype; Influenza A virus H3N2 subtype; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 18 Feb 2011 New trial record
- 31 Dec 2010 Results published in Vaccine.